Nasdaq

AEON Biopharma Completes BPD Type 2a Meeting With FDA

(RTTNews) - AEON Biopharma, Inc. (AEON), a biopharmaceutical company that develops ABP-450 as a biosimilar to BOTOX, reported that it held a BPD Type 2a meeting with the FDA in addition to the closure ...
Yahoo Finance

AEON Biopharma Reports BPD Type 2a Meeting with FDA and Shareholder Approval of the November Transactions

IRVINE, Calif., Jan. 21, 2026 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE American: AEON), a biopharmaceutical company seeking accelerated and full-label U.S. market entry ...
Nasdaq

AEON Biopharma Announces First Closing of PIPE Investment and Provides Update on FDA Type 2a Meeting Scheduling

IRVINE, Calif., Nov. 20, 2025 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE American: AEON), a biopharmaceutical company seeking accelerated and full-label U.S. market entry ...
Finanznachrichten

AEON Biopharma Inc: AEON Biopharma Reports BPD Type 2a Meeting with FDA and Shareholder Approval of the November Transactions

- AEON confirmed that earlier today it held its BPD Type 2a Meeting with the FDA, in line with prior guidance, and is now awaiting official meeting minutes- - Separately, AEON shareholders today voted ...